Background-Randomized trials have demonstrated the efficacy of several new therapies for heart failure (HF) with reduced ejection fraction over the preceding 2 decades. This study investigates whether these therapeutic advances have translated into improvement in outcomes for patients with advanced HF referred to a heart transplant center. Methods and Results-Patients with HF (n=2507) referred to a single university center were analyzed in three 6-year eras during which medical and device therapies were evolving: 1993 to 1998 (era 1), 1999 to 2004 (era 2), and 2005 to 2010 (era 3). Impaired hemodynamics and comorbidities were more frequent at time of referral in later eras, whereas other HF severity parameters where similar or improved. Successive eras had greater usage of angiotensinconverting enzyme inhibitors/angiotensin receptor blockers, β-blockers, aldosterone antagonists, implantable cardioverter defibrillators, and cardiac resynchronization therapy, consistent with evolving evidence and guideline recommendations over the study period. All-cause mortality and sudden death were significantly lower in era 2 and 3 compared with era 1. After multivariable risk adjustment, era 3 had significantly decreased 2-and 3-year all-cause mortality risk and significantly decreased 1-and 3-year sudden death risk compared with era 1. However, progressive HF death and the combined outcome of mortality/urgent transplant/ventricular assist device were modestly increased in the latter eras. Conclusions-Over the past 2 decades, patients with advanced HF referred to and managed at a tertiary university referral center have benefited from advances in HF medications and devices, as evidenced by improvements in overall survival and sudden death risk. (Circ Heart Fail. 2013;6:411-419.)
I n the last 2 decades, randomized trials have identified several therapies that are efficacious in patients with heart failure (HF) and reduced ejection fraction (EF). 1 Angiotensinconverting enzyme inhibitors or angiotensin receptor blockers, β-blockers, and aldosterone antagonists have been shown to prolong survival in large randomized, placebo-controlled trials, forming the foundation of medical therapy for HF with reduced EF. [2] [3] [4] [5] [6] [7] [8] Major trials have also demonstrated the efficacy of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) in improving outcomes of select patients with HF and reduced EF. [9] [10] [11] [12] [13] [14] Implementation of HF medical and device therapies associated with survival benefit in clinical trials is expected to improve survival in real-world HF populations. However, communityand population-based studies that consider temporal trends in outcomes have generally not examined long-term survival rates in advanced referral HF populations after the advent of modern medical and device therapies. [15] [16] [17] [18] [19] [20] [21] There are also other factors that may impact survival in patients with advanced HF, including differences in disease severity at time of referral, longer waiting times on heart transplant lists, and the increasing availability of ventricular assist devices (VADs). This study examines trends in treatment and outcomes in patients with advanced HF and reduced EF presenting to a university referral center for HF management or transplant/VAD evaluation between 1993 and 2010, a time period during which there were significant advances in medical and device therapies for HF. 
Methods

Patients
The study was composed of consecutive patients referred to the Ahmanson-University of California, Los Angeles Cardiomyopathy Center from 1993 to 2010. All patients were followed in a comprehensive management program for HF, as previously described. 22 Patients with left ventricular EF >40% (n=1881) were excluded from this study. The remaining patients (n=2507) were considered in three 6-year eras, 1993 to 1998 (era 1, n=793), 1999 to 2004 (era 2, n=879), and 2005 to 2010 (era 3, n=835), a time period during which HF therapies were evolving, specifically with the introduction of β-blockers, aldosterone antagonists, ICDs, and CRT. A previous publication from our center reported on temporal trends in clinical outcomes from 1986 to 1993. 23 Review of medical records was approved by the University of California, Los Angeles, Medical Institutional Review Board.
Baseline Data
Medications were recorded at time of referral and every visit thereafter. Diuretic doses were converted to furosemide equivalents. The formula used to convert other loop diuretics to furosemide equivalents was as follows: furosemide 80 mg = torsemide 40 mg = bumetanide 3 mg = ethacrynic acid 50 mg. Laboratory testing, echocardiography, and cardiopulmonary exercise tests analyzed in this study all occurred within 3 months of initial referral. EF and dimensions were extracted from echocardiography reports; left ventricular end-diastolic dimension index (LVEDDI) was calculated as LVEDDI = left ventricular end-diastolic dimension/body surface area. Past medical history was extracted from medical record review. Device therapy (CRT or ICD) in this study was considered present if the device had been placed before referral, or within 3 months of referral. Hemodynamic variables used in the analyses were the optimal values recorded after pulmonary artery catheter-tailored medical therapy because these measurements have been shown to best correlate with survival.
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End Points
The primary end point analyzed was all-cause mortality. Secondary end points analyzed were sudden death, progressive HF death, urgent transplant (United Network for Organ Sharing status IA), VAD, and the combined end point of death, urgent transplant, and VAD. All end points were assessed at 1, 2, and 3 years. Nonurgent transplants (status IB and II) were censored and considered as a nonfatal end of follow-up for the combined end point. Death was considered sudden if it was unexpected based on the patient's clinical status, and if it occurred out of the hospital within 15 minutes of the onset of unexpected symptoms or during sleep, as defined previously. 23 Death during hospitalization for worsening congestive symptoms was considered a progressive HF death.
Statistical Analysis
Differences in baseline data among the 3 eras were analyzed using Pearson χ 2 test, 1-way ANOVA, and nonparametric tests, as appropriate. Actuarial event curves for each era were calculated by the Kaplan-Meier method, and differences in the curves were assessed by the log-rank statistic. Multivariable analyses adjusting for established predictors of HF outcomes, including age, sex, left ventricular EF, New York Heart Association (NYHA) class, body mass index, history of coronary artery disease, history of diabetes mellitus, history of hypertension, total cholesterol, serum sodium, serum blood urea nitrogen, and pulmonary capillary wedge pressure after optimization of therapy, were performed by Cox proportional hazards regression analysis to estimate adjusted hazard ratios and 95% confidence intervals. The Cox model retained all independent variables with P<0. 15 . Tests for trend were performed with the Cochran-Armitage test for actuarial and adjusted survival across the eras. Adjusted hazard curves were estimated graphically as 1 -survival using the Cox model. To evaluate the severity of illness at the time of referral, mortality risk scores and expected 1-and 3-year mortality rates for patients in each of the 3 eras were calculated using the Seattle HF Model (excluding adjustment for medications, other than loop diuretic doses, and devices), a previously developed model for predicting mortality in patients with HF. 25 All tests were 2-sided with P<0.05 considered statistically significant. All analyses were calculated using PASW (Predictive Analytics Software) Statistics, version 18.0 (IBM, Somers, NY).
Results
Patient characteristics for each era are shown in Table 1 . Patients were 74% men with a mean age of 53 years. The left ventricular EF at the time of referral was slightly lower in era 3 compared with the previous 2 eras (P<0.001). Diabetes mellitus and body mass index were higher in latter eras, and B-type natriuretic peptide levels were higher in era 3 compared with era 2 (P<0.001). Lower left ventricular end-diastolic dimension index and lower total cholesterol were also observed in later eras (P<0.001). The proportion of patients that were classified as NYHA class IV functional class was lower in eras 2 and 3, with a concomitantly higher proportion of patients having NYHA class II and III disease (P<0.001). In terms of hemodynamic variables, heart rate was lower, whereas right atrial pressure, systolic pulmonary artery pressure, and pulmonary capillary wedge pressure were higher in latter eras (P<0.001). The Seattle HF Risk Model score was highest in era 3 (P=0.004) ( Table 1) .
Management of HF
As expected, use of HF therapies varied strikingly across the eras ( Table 2 ). The proportion of patients receiving aldosterone antagonists, β-blockers, ICD, and CRT was substantially higher in the latter eras (P<0.001). Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers use remained at a high level in all eras with a small decrease seen in era 3 compared with era 2. Nitrates, hydralazine, and loop diuretics were used by fewer patients in latter eras. The proportion of patients receiving anticoagulation was unchanged over the study period.
Temporal Trends in Outcomes
The primary outcome of all-cause mortality was significantly lower at 1 and 3 years in era 2 and 3 (Table 3 and Figure 1 ). Sudden death was lower in latter eras (Table 3 and Figure 2 ). However, mortality from progressive HF death was higher in era 3 compared with era 1 (Table 3 and Figure 2 ). The combined end point of all-cause mortality, urgent transplant, or VAD was lower in era 2 but was higher in era 3 ( Figure 1 ). This is largely accounted for by the higher rate of urgent heart transplantation (United Network for Organ Sharing status IA) and VAD implantation in the last era (Table 3 ). There were lower rates of nonurgent heart transplantation in era 2 and 3 ( Table 3 ). The median times from referral to urgent transplantation were similar in all 3 eras (2.1, 2.4, and 2.1 months; P=0.929). The time from referral to nonurgent transplantation also did not statistically differ in the 3 eras (8.5, 11.9, and 7.8 months; P=0.091). C and D) . Risk-adjusted survival curves are adjusted for patients' age, sex, left ventricular ejection fraction, New York Heart Association class, body mass index, history of coronary artery disease, history of diabetes mellitus, history of hypertension, total cholesterol, serum sodium, serum blood urea nitrogen, and pulmonary capillary wedge pressure after optimization of therapy. Probability values for unadjusted curves (A and C) are derived from log-rank statistic. P values for adjusted curves (B and D) are derived from Cochran-Armitage trend test.
Risk-Adjusted Analysis of Outcomes
After adjusting for known predictors of HF mortality, era 3 was independently associated with decreased risk of allcause mortality compared with era 1 at 2 and 3 years, with a borderline P value at 1-year follow-up (Table 4 and Figure 1 ). Compared with era 1, era 3 was associated with a 42% lower adjusted relative risk of mortality during 3-year follow-up (hazard ratio, 0.58; 95% confidence interval, 0.40-0.85). Era 3 was independently associated with decreased risk of sudden death compared with era 1 at 1 and 3 years, with a borderline P value (P=0.057) for decreased risk at 2 years (Table 4 and Figure 2 ). In contrast, after multivariable adjustment, latter eras were not independently associated with lower or higher risk of progressive HF death with the exception of a higher risk seen for era 2 at 1 year. After multivariable analysis, era 2 had a higher risk of the combined end point of mortality, urgent transplant, or VAD (Table 4 ). Unadjusted and riskadjusted hazard curves for the outcome of all-cause mortality and the composite of mortality, urgent transplant, or VAD are shown in Figure 1 .
Discussion
The major findings of this study are that over successive time periods from 1993 to 2010, there has been a marked increase in the use of evidence-based therapies in patients with advanced HF and reduced EF referred to a tertiary university HF center, with a corresponding improvement in overall survival in this patient population. Sudden cardiac death was also significantly lower in latter eras. Concomitant with a substantial decrease in sudden death was a modest increase in progressive HF death, urgent transplants, and VADs. After risk adjustment, there was a lower risk of all-cause mortality and sudden death for patients treated in the 2005 to 2010 time frame compared with 1993 to 1998. Although rates of progressive HF death were high in the latter eras, this is not surprising given that sudden deaths were significantly lower in latter eras and likely reflects a shifting mode of death. These findings confirm the successful translation of evidence-based care in treatment of patients with HF and reduced EF from clinical trials to patients in real-world clinical practice. The severity of HF disease state at time of referral to our university center seems to be worsened in latter eras in our HF population by some, but not other, measures. Over the past 2 decades, as documented in this study, patients in the latter eras had modest but significantly worse hemodynamic status, as indicated by higher pulmonary artery pressure, higher pulmonary capillary wedge pressure, and lower cardiac index, measured after medical optimization. Furthermore, Seattle HF Model risk score and predicted mortality were highest in the last era. However, other individual parameters, including NYHA class, peak VO 2 , left ventricular end-diastolic dimension, systolic blood pressure, and heart rate, did not indicate increased disease state severity at the time of referral. A previous publication reporting on temporal trends in clinical outcomes at our center from an earlier time period 1986 to 1993 found that patients in the different time periods had similar hemodynamic variables after tailored therapy. 23 This study cohort also has increased comorbidities in latter eras as indicated by higher rates of diabetes mellitus and atrial fibrillation, lower hemoglobin levels, and higher creatinine levels in the latter eras; this increase in comorbidities over time is congruent with findings from other studies of HF populations. In an epidemiological study of HF in Western Australia, Teng et al 19 found that prevalence of ischemic heart disease fell, whereas prevalence of hypertension, diabetes mellitus, atrial fibrillation, and renal failure rose from 1990 to 2003. One study of Medicare beneficiaries hospitalized for HF found increased prevalence of hypertension, diabetes mellitus, anemia, and pneumonia from 1993 to 2006, whereas another study described increased prevalence of hypertension and renal failure 16, 18 ; similar trends in prevalence of comorbid conditions are noted in our population.
The successful translation of life-prolonging medications and devices for HF and reduced EF, from clinical trial to real-world populations, seen in this study is echoed in other publications of HF trends over the past decades. Jhund et al 26 showed significant increases in prescribing rates of angiotensin-converting enzyme inhibitors, β-blockers, and spironolactone from 1986 to 2003 for patients with HF in Scotland. More recently, Cubbon et al 27 found an increased usage of medications, ICD, and CRT in 2006 to 2009 cohort compared with 1993 to 1995 cohort of patients with stable HF in the United Kingdom. Our study extends this finding to a population of patients with advanced HF referred to a tertiary center for heart transplant or VAD evaluation, with higher rates of β-blocker and aldosterone antagonist use, as well as device implantation seen in the latter eras of treatment.
Community, population, and cohort studies have shown improved survival in HF populations over the past 2 decades, similar to the trends observed in the present analysis. An older study from a community cohort in Olmstead County, Minnesota showed reduced mortality in men after onset of HF from 26% in 1985 to 1990 to 21% in 1996 to 2000. 21 Several additional studies have shown general improvement in survival after hospitalization for HF 16, 18, 19, 26, 28 ; US Medicare beneficiaries had modest increases in 30-day and 1-year survival after hospitalization for HF, with the number of hospitalizations falling from 1998 to 2008. 16, 18 Jhund et al 26 also showed that mortality after hospitalization for HF fell in Scotland from 1995 to 2003, coinciding with the increase in prescribing rates for angiotensin-converting enzyme inhibitorss, β-blockers, and spironolactone during this time period. A larger 38% decrease in all-cause mortality at 1 year between 1993 and 1995 cohort and 2006 and 2009 cohort of stable patients with HF in the United Kingdom was demonstrated by Cubbon et al. 27 Singh et al 29 found that the risk of dying while listed for heart transplant or becoming too sick for transplant has decreased in the United States after the implementation of a new sharing algorithm for these organs in 2006. Our study of an advanced HF population referred to a tertiary center for heart transplant or VAD evaluation demonstrates a 13% and 42% lower risk of all-cause mortality at 3 years for eras 2 and 3, respectively (P trend=0.006), compared with era 1 among . Sudden death, non-sudden death, and total mortality at 1 year in the 3 eras, (A) unadjusted and (B) adjusted rates. Risk-adjusted survival curves are adjusted for patients' age, sex, left ventricular ejection fraction, New York Heart Association class, body mass index, history of coronary artery disease, history of diabetes mellitus, history of hypertension, total cholesterol, serum sodium, serum blood urea nitrogen, and pulmonary capillary wedge pressure after optimization of therapy.
patients with reduced EF treated at our center after adjustment for multiple known predictors of HF mortality.
Outcomes in patients with advanced HF over the past 20 years may also have been influenced by differences in waiting times for transplantation, rates of transplantation, and use of VADs in the 3 eras. In our cohort, waiting times for urgent and nonurgent transplantation did not significantly change during the 3 eras, suggesting differences in transplantation waiting times are unlikely to account for the improved survival in latter eras. There were, however, higher rates of urgent transplantation in era 3 that may contribute to the lower mortality rates observed. However, there was also a decrease in nonurgent transplants, which may in part account for the higher rate of urgent transplants. Finally, the use of VADs remained low across the eras, even in era 3, suggesting access to this new technology did not significantly affect the differences in outcomes.
Study Limitations
We acknowledge some limitations to our study. This study is observational and evaluates a cohort of patients with advanced HF referred to a single university center. Because it was observational in nature, we cannot establish causality between increased use of evidence-based therapies and decreased mortality observed over the study period. Also, we cannot exclude that other factors, such as increased understanding of and compliance with lifestyle modifications and HF disease management, may be reflected in our results. Our findings reflect a single center referral experience, and findings may not be able to be generalized to other settings. Although we adjusted for multiple variables of established prognostic significance in patients with advanced HF, there are other established markers that were not included. The assessment of NYHA class potentially shifted over time with differing clinician experience expectations; in era 1, the majority of the patients (58%) were classified as NYHA IV, whereas, in era 2 and 3, only 29% of patients were classified as NYHA IV, even though other measures of HF severity were similar or worse. There may be residual measured and unmeasured confounding variables that account for some or all of these findings. There are also well-recognized limitations in distinguishing between different modes of death in patients with HF, so the findings regarding different time trends in mode of death should be interpreted with these limitations in mind. Finally, the time period of our study predates a more recent increase in VAD usage, and so we cannot determine how higher rates of VAD usage may affect long-term HF outcomes.
Conclusions
In a cohort of patients with advanced HF and reduced EF referred to and managed at a tertiary university referral center from 1993 to 2010, there has been successive application of evidence-based, guideline-recommended therapies, coincident with improvement in overall survival, and lower sudden death risk over time. Increased rates of HF deaths, transplants, and VADs in the latter eras were seen and are potentially attributable to different risk profiles at the time of referral and substantial reductions in sudden death in latter eras. Finally, despite improvement in survival over the past 2 decades, the all-cause mortality rate for advanced HF with reduced EF at 3 years remains at ≈30%, indicating the need to continue seeking new treatment options and management strategies for this prevalent problem with significant relevance to public health. 
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